Active Ingredient
Salicylic acid 2.0%
Clarity Clear Skin Essentials
- Manufacturer
- Melaleuca Inc.
- Effective date
- 2023-01-05
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 5
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 21:41:47
Label at a glance#
ProductClarity Clear Skin Essentials Acne Spot Treatment
Active ingredientSALICYLIC ACID
Label structure10 sections
Label contents#
Full prescribing information#
Purpose
Acne Treatment
INDICATIONS & USAGE SECTION
Use for the treatment and management of acne
Warnings
For external use only. Do not get into eyes. If contact occurs, rinse eyes thoroughly with water.
OTC - WHEN USING SECTION
When using this product skin irritation and dryness is more likely top occur if you use another topical acne medication at the same time. If this occurs, only one acne medication should be used unless otherwise directed by a doctor.
OTC - STOP USE SECTION
Stop use and ask a doctor if excessive irritation of the skin develops
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
DOSAGE & ADMINISTRATION SECTION
Directions • clean skin thoroughly before applying this product • cover the entire affected area with a thin layer one to three times daily • because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor • if bothersome dryness or peeling occurs, reduce application to once a day or every other day
INACTIVE INGREDIENT SECTION
Inactive ingredients butylene glycol, fragrance, hamamalis virginiana (witch hazel) extract, hydroxypropyl beta cyclodextrin, melaleuca alternifolia (tea Tree) leaf oil, menthol, SD alcohol 40-B, water
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54473-225-01 | 2025-03-17 | C162847 | 48780-1 | 9d75b9d0-c14e-f424-e053-dadaa90a57ce | Clarity Clear Skin Essentials Acne Spot Treatment |
| 54473-225-01 | 2025-01-30 | C162847 | 48780-1 | 9d75b9d0-c14e-f424-e053-dadaa90a57ce | Clarity Clear Skin Essentials Acne Spot Treatment |
| 54473-225-01 | 2020-03-19 | C162847 | 48780-1 | 9d75b9d0-c14e-f424-e053-dadaa90a57ce | Clarity Clear Skin Essentials Acne Spot Treatment |
| 54473-225-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-c14e-f424-e053-dadaa90a57ce | Clarity Clear Skin Essentials Acne Spot Treatment |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SALICYLIC ACID | ACTIVE INGREDIENT | O414PZ4LPZ | 2 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 2 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| HAMAMELIS VIRGINIANA TOP | INACTIVE INGREDIENT | UDA30A2JJY | 2 | |
| MENTHOL | INACTIVE INGREDIENT | L7T10EIP3A | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- Clarity Clear Skin Essentials Acne Spot Treatment
- SALICYLIC ACID
- WATER
- HAMAMELIS VIRGINIANA TOP
- BUTYLENE GLYCOL
- MENTHOL
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 54473-225 | 54473-225-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| HAMAMELIS VIRGINIANA TOP | UDA30A2JJY | IACT |
| BUTYLENE GLYCOL | 3XUS85K0RA | IACT |
| MENTHOL | L7T10EIP3A | IACT |
| SALICYLIC ACID | O414PZ4LPZ | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MENTHOL | MENTHOL | L7T10EIP3A | GEL / TOPICAL | 0.1 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SYRUP / ORAL | 7.5 mg/5ml | ||
| MENTHOL | MENTHOL | L7T10EIP3A | TABLET / ORAL | 0.58 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.02 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | TABLET, ORALLY DISINTEGRATING / ORAL | 14 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | GUM, CHEWING / BUCCAL | 89 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | DROPS / NASAL | 40.32 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | POWDER, FOR SOLUTION / ORAL | NA | ||
| MENTHOL | MENTHOL | L7T10EIP3A | DROPS / OPHTHALMIC | NA | ||
| MENTHOL | MENTHOL | L7T10EIP3A | CAPSULE / ORAL | 0.87 mg | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SOAP / TOPICAL | 0.75 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 0.02 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SOLUTION / ORAL | 3 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SOLUTION, CONCENTRATE / ORAL | 0.5 mg/1ml | ||
| MENTHOL | MENTHOL | L7T10EIP3A | INHALANT / NASAL | 32 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | LOTION / TOPICAL | 0.05 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SOLUTION / DENTAL | NA | ||
| MENTHOL | MENTHOL | L7T10EIP3A | CONCENTRATE / ORAL | 0.05 mg/5ml | ||
| MENTHOL | MENTHOL | L7T10EIP3A | PASTE, DENTIFRICE / DENTAL | 4.7 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | JELLY / NASAL | 32.5 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | TABLET / SUBLINGUAL | 2 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | CREAM / TOPICAL | 0.1 %w/w | ||
| MENTHOL | MENTHOL | L7T10EIP3A | SUSPENSION / ORAL | 1 mg | ||
| MENTHOL | MENTHOL | L7T10EIP3A | MOUTHWASH / BUCCAL | 0.15 mg/1ml | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TOPICAL | 1400 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 308e48a0-d80d-ca9f-e063-6394a90a5968 | df33b7ba-f2b2-4031-8b27-9d0b27e256fe | 2025-03-17 | Warnings | df33b7ba-f2b2-4031-8b27-9d0b27e256fe |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.